Evolution of hepatitis B serological markers in HIV coinfected patients: a case study

Imagem de Miniatura
Arquivos
art_TOSCANO_Evolution_of_hepatitis_B_serological_markers_in_HIV_2017.PDF (171.19 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2017
Editora
REVISTA DE SAUDE PUBLICA
DOI
Indexadores
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
REVISTA DE SAUDE PUBLICA, v.51, article ID 24, 8p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS: The study population consisted of patients met in an AIDS Outpatient Clinic in Sao Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS: Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B ""e"" antigen positive at the first assessment. Clearance of hepatitis B surface antigen occurred in 15% (16/105) of patients with chronic hepatitis B, and 50% (8/16) of these patients presented subsequent reactivation or seroreversion of hepatitis B surface antigen. Among hepatitis B ""e"" antigen positive patients, 57% (35/61) presented clearance of this serologic marker. During clinical follow up, 28.5% (10/35) of those who initially cleared hepatitis B ""e"" antigen presented seroreversion or reactivation of this marker. CONCLUSIONS: Among HIV coinfected patients under antiretroviral therapy, changes of HBV serological markers were frequently observed. These results suggest that frequent monitoring of these serum markers should be recommended.
Palavras-chave
HIV infection, Hepatitis B, Chronic, immunology, Coinfection, Biomarkers, Seroepidemiologic Studies
URI
https://observatorio.fm.usp.br/handle/OPI/20060
Referências
  1. Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
  2. Avelino-Silva VI, 2013, HIV MED, V14, P453, DOI 10.1111/hiv.12040
  3. Benhamou Y, 1999, HEPATOLOGY, V30, P1302, DOI 10.1002/hep.510300525
  4. da Silva AC, 2010, MEM I OSWALDO CRUZ, V105, P770, DOI 10.1590/S0074-02762010000600007
  5. Di Martino V, 2002, GASTROENTEROLOGY, V123, P1812, DOI 10.1053/gast.2002.37061
  6. Gilson RJC, 1997, AIDS, V11, P597, DOI 10.1097/00002030-199705000-00007
  7. Idoko J, 2009, CLIN INFECT DIS, V49, P1268, DOI 10.1086/605675
  8. Kato H, 2002, J VIROL, V76, P6131, DOI 10.1128/JVI.76.12.6131-6137.2002
  9. Kosi L, 2012, J VIRAL HEPATITIS, V19, P801, DOI 10.1111/j.1365-2893.2012.01601.x
  10. Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
  11. Lin SM, 2007, J HEPATOL, V46, P45, DOI 10.1016/j.jhep.2006.08.021
  12. Livingston SE, 2007, GASTROENTEROLOGY, V133, P1452, DOI 10.1053/j.gastro.2007.08.010
  13. Lu ZH, 2011, J INT MED RES, V39, P71
  14. Manegold C, 2001, CLIN INFECT DIS, V32, P144, DOI 10.1086/317535
  15. Matthews GV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061297
  16. Matthews GV, 2006, AIDS, V20, P863, DOI 10.1097/01.aids.0000218550.85081.59
  17. Maylin S, 2012, AIDS, V26, P939, DOI 10.1097/QAD.0b013e328352224d
  18. Nunez M, 2006, AIDS RES HUM RETROV, V22, P842, DOI 10.1089/aid.2006.22.842
  19. Piroth L, 2002, J HEPATOL, V36, P681, DOI 10.1016/S0168-8278(02)00019-3
  20. Puoti M, 2006, J HEPATOL, V44, pS65, DOI 10.1016/j.jhep.2005.11.015
  21. Rabenau H, 1996, INFUSIONSTHERAPIE, V23, P124
  22. Sheng WH, 2007, CLIN INFECT DIS, V45, P1221, DOI 10.1086/522173
  23. Taffon S, 2014, INFECTION, V42, P675, DOI 10.1007/s15010-014-0616-2
  24. Velasco M, 1999, NEW ENGL J MED, V340, P1765, DOI 10.1056/NEJM199906033402215
  25. Wang HL, 2012, AIDS, V26, P1755, DOI 10.1097/QAD.0b013e328355ced2

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03